Business Wire

Ferring’s Heat-Stable Carbetocin Could Save Thousands of Women’s Lives by Preventing Excessive Bleeding after Childbirth

Jaa

Ferring Pharmaceuticals today announced new data demonstrating that its heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive bleeding, also known as postpartum haemorrhage (PPH), after vaginal birth.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180627005996/en/

Heat-barrier infographic (Graphic: Business Wire)

Heat-barrier infographic (Graphic: Business Wire)

Results from the CHAMPION clinical trial, conducted by the World Health Organization (WHO) as part of a collaboration with Ferring and MSD for Mothers ** , were published in the New England Journal of Medicine (NEJM).1 This is the largest study conducted in the prevention of PPH with nearly 30,000 women in ten countries.1

Every year, 14 million women are affected by PPH.2 Although most deaths are preventable,3 PPH is the leading direct cause of maternal death worldwide,4 causing approximately 70,000 deaths per year.4

This is an important step forwards in PPH prevention and these results pave the way for heat-stable carbetocin to potentially save the lives of thousands of women, especially in areas where cold-chain transport and storage is not feasible,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “We will now work with the WHO and MSD for Mothers to make heat-stable carbetocin available in countries where it is needed most, protecting women and families around the world.”

Researched and developed by Ferring as a solution to address unmet needs in women’s health, heat-stable carbetocin remains effective at high temperatures,5 addressing a significant limitation of oxytocin which must be stored and transported at 2 – 8°C. 6,7 Studies in low- and lower-middle income countries have revealed degradation and loss of efficacy in oxytocin ampoules, which could be due to inadequate storage and distribution conditions.7,8 Data show that heat-stable carbetocin maintains effectiveness for at least three years at 30°C and six months at 40°C.5 Heat-stable carbetocin has the potential to save thousands of women’s lives in low- and lower-middle income countries, where 99% of PPH-related deaths occur2 and where the refrigeration of medicines can be difficult to achieve and maintain.6

The CHAMPION trial was conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), using Ferring’s heat-stable carbetocin, and funded by MSD for Mothers.1,6 Ferring will now seek registrations and manufacture heat-stable carbetocin. The parties will work together with the aim of making heat-stable carbetocin available at an affordable and sustainable price in the public sector of low- and lower-middle income countries that have a high burden of maternal mortality.

* The availability of heat-stable carbetocin is subject to regulatory review and approval in relevant countries.

** Known as Merck & Co., Inc., Kenilworth, N.J., U.S.A.

About the CHAMPION trial 1
CHAMPION, (Carbetocin Haemorhage Prevention), the largest clinical trial in the prevention of PPH, was a double-blind, randomised, non-inferiority trial designed to compare the effectiveness and safety of investigational heat-stable carbetocin to oxytocin in the prevention of PPH after vaginal birth. The trial, conducted by the WHO Department of Reproductive Health and Research including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in HRP, enrolled nearly 30,000 women in ten countries including Argentina, Egypt, India, Kenya, Nigeria, Singapore, South Africa, Thailand, Uganda and the UK. Heat-stable carbetocin was researched and developed by Ferring Pharmaceuticals and the CHAMPION trial was funded by MSD for Mothers.

Results demonstrated that heat-stable carbetocin is clinically non-inferior to oxytocin for the primary outcome of ≥500 ml blood loss or additional uterotonic use. The frequency of blood loss of ≥500 ml or additional uterotonic use was 14.5% in the carbetocin group and 14.4% in the oxytocin group (Relative Risk (RR): 1.01 95% confidence interval (CI) 0.95 to 1.06), consistent with non-inferiority.

Non-inferiority was not demonstrated for the second primary outcome of blood loss of ≥ 1,000 ml (1.51% carbetocin group vs 1.45% in the oxytocin group, RR: 1.04, CI: 0.87 to 1.25); however, the trial was underpowered for this outcome. There were no significant differences between groups in other measures of bleeding or in adverse effects.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

# # #

References
1 Widmer M, et al. Heat stable carbetocin vs oxytocin to prevent hemorrhage after vaginal birth. New England Journal of Medicine 2018;in press.
2 World Health Organization. Priority diseases and reasons for inclusion. Postpartum haemorrhage. Available at: http://www.who.int/medicines/areas/priority_medicines/Ch6_16PPH.pdf Last accessed: May 2018.
3 World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Published 2012. Available at: http://apps.who.int/irisbitstream/10665/75411/1/9789241548502_eng.pdf Last accessed: May 2018.
4 Say L, et al. Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health. 2014; 2(6):e323-33. Available at: https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(14)70227-X.pdf Last accessed: May 2018.
5 Malm M, et al. Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries. Journal of Peptide Science 2018;e3082.
6 Widmer M, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage during the third stage of labour in women delivering vaginally: study protocol for a randomized controlled trial. Trials 2016;17(1):143.
7 Torloni MR, et al. Quality of Oxytocin Available in Low and Middle-Income Countries: A Systematic Review of the Literature (Systematic Review on Quality of Oxytocin). An International Journal of Obstetrics and Gynaecology 2016;123(13):2076-2086.
8 Anyakora, et al. Quality medicines in maternal health: results of oxytocin, misoprostol, magnesium sulfate and calcium gluconate quality audits. BMC Pregnancy and Childbirth 2018;18:44.

Contact information

Ferring Pharmaceuticals
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
or
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Patrick Gorman
Director, Ferring Pharmaceuticals USA
+1 862 286 5035 (direct)
patrick.gorman@ferring.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Rockwell Automation Opens Registration for 2018 Automation Fair18.9.2018 17:54Tiedote

Registration is now open for the 2018 Automation Fair, hosted by Rockwell Automation and members of its global PartnerNetwork program. The 27th annual Automation Fair will be held Nov. 12-15 at the Pennsylvania Convention Center. The event brings together approximately 10,000 manufacturers and producers from across the globe to learn about the newest innovations in automation and take part in training, industry forums and networking events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005725/en/ Automation Fair will feature more than 150 exhibits showcasing the latest product innovations for industrial manufacturing and production. Hosted by Rockwell Automation and members of its PartnerNetwork, the event offers more than 400 hours of educational opportunities through forums, hands-on labs and technical sessions. (Photo: Business Wire) “The next industrial transformation is here – and meeting its demands requires a m

Seoul Semiconductor Supplies Optimal LEDs ‘SunLike’ to Large Scale Applications of Lumitronix in Germany18.9.2018 16:33Tiedote

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, supplied the innovative LEDs “SunLike” to Lumitronix, the LED specialist located in Baden-Württemberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005626/en/ The Modules with SunLike LEDs. (Photo: Business Wire) In cooperation with Seoul Semiconductor, Lumitronix has also developed three optimal SunLike modules to provide customers with a standardized solution and expand its adoption in the lighting market. Two of the LED modules comply with the standard of Zhaga, a global association of lighting companies, for Book 7 L56W2 and Book 7 L28W2 and enable easy replacement in various industrial applications. The modules named LinearZ are available in one feet and two feet length. The model LinearZ 280-26 measures 280 mm and is equipped with 26 SunLike LEDs and has a light output of up to 700 lm.

Andersen Global Continues South American Expansion With BKM Berkemeyer18.9.2018 16:30Tiedote

Andersen Global announces further growth in South America with the signing of a Collaboration Agreement with BKM Berkemeyer, one of the oldest and largest law firms in Paraguay. With two locations in the capital city of Asunción, the firm has a headcount of nearly 150 professionals, including ten Partners and over 60 lawyers. Established in 1951, BKM Berkemeyer is led by Managing Partner Hugo Berkemeyer and provides legal solutions to both domestic and international clients. The firm delivers advice in all areas of law, including business and corporate, taxation, litigation, environment, employment and intellectual property, with a notable expertise in international transactions and business matters. BKM Berkemeyer also specializes in M&A’s, joint ventures, foreign investment, infrastructure, project finance and financial transactions, advising also on issues regarding telecommunications, water and energy projects. Hugo commented, “Our focus at BKM Berkemeyer has been to provide flexib

175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis18.9.2018 16:05Tiedote

Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnoea, meaning they experience at least 15 breathing events an hour during sleep. These statistics are based on the latest scoring rules for determining one’s apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life. The new global prevalence is nearly tenfold higher than the previous one – 100 million – estimated by the World Health Organization in 2007. European countries with the highest prevalence are: Russia, 40 million Germany, 26 million France, 24 million Ukraine, 13 million Sp

Veteran Gartner Analyst Pat Phelan Joins Rimini Street as VP of Market Research18.9.2018 16:00Tiedote

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of Pat Phelan as vice president of market research. In this new role, Phelan is responsible for research across the enterprise software market, including applications and technology strategies, software vendor support, third-party support, IT leadership trends and IT optimization. She also supports strategic planning, senior leadership discussions, business development and sales execution by providing enterprise software licensees with quantitative and qualitative strategic insights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005304/en/ Veteran Gartner Analyst Pat Phelan Joins Rimini Street as VP of Market Research (Photo: Business Wire) “As a Gartner analyst, I closely followed Rimini Street since its

AGCO Launches AGCO Agriculture Foundation18.9.2018 16:00Tiedote

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and solutions, today announced the launch of the AGCO Agriculture Foundation. “The AGCO Agriculture Foundation is a testament to our commitment to support farmers feeding the world. Our objective is to support non-profit initiatives that contribute to global food security, support sustainable agriculture development and have an economic impact in developing countries,” said Martin Richenhagen, AGCO’s Chairman, President and CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005073/en/ The new philanthropic focus demonstrates AGCO’s strong commitment to specific Sustainable Development Goals developed by the United Nations that seek to end hunger and provide basic necessities to a growing world population. AGCO has already been driving change globally, particularly in certain developing markets, by supporting farmer

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme